Clinical advances in therapies targeting the interleukin-2 receptor

QJM: An International Journal of Medicine

Volumn 96, Issue 2, 2003, Pages 91-102

  Church, A C ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; PREDNISOLONE; PROTEIN ANTIBODY; RECOMBINANT INTERLEUKIN 2; TAC ANTIBODY FV PE38; UNCLASSIFIED DRUG; ZENAPEX;

ANTIGEN PRESENTING CELL; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; BINDING AFFINITY; CHROMOSOME 4; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG TARGETING; GRAFT REJECTION; HELPER CELL; HUMAN; LYMPHOCYTE DIFFERENTIATION; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN STRUCTURE; RASH; RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0037291111     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hcg014     Document Type: Review

References (86)

1. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T-lymphocytes from human bone marrow. Science 1976; 193:1007-8.
2. Brandhuber BJ, Boone T. Three-dimensional structure of IL-2. Science 1987; 238:1707-9.
3. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248:1349-6.
4. Smith KA. T-cell growth factor. Immunol Rev 1980; 51:337-57.
5. Robb RJ, Munck A, Smith KA. T cell growth factor receptors: quantitation, specific and biological relevance. J Exp Med 1981; 154:1455-74.
6. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. J Immunol 1981; 126:1398-403.
7. Leonard WJ, Depper JM, Crabtree GR, Rudikoff J, Pumphery J, Robb J, et al. Molecular cloning and expression of cDNA for the human interleukin-2 receptor. Nature 1984; 311:626-31.
8. Tsudo M, Kozak RW, Goldman CK, Waldmann TA. Demonstration of a new (non-Tac) peptide that binds interleukin-2: a potential participant in a multichain interleukin-2 complex. Proc Natl Acad Sci USA 1986; 83:9694-8.
9. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, et al. Cloning of the α-chain of the human IL-2 receptor. Science 1992; 257:379-82.
10. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998; 70:1-81.
11. Leonard WJ, Depper JM, Kronke M, Peffer NJ, Svetlik PB, et al. Structure of the human interleukin-2 receptor gene. Science 1985; 230:633-9.
12. Waldmann TA. The interleukin-2 receptor. Ann Rev Biochem 1989; 58:875-911.
13. Anderson DM, Kumaki S, Ahdieh M, Bertles J, Tometsko M, Loomis A, et al. Functional characterisation of the human interleukin-15 receptor alpha chain and close linkage of IL-15RA and IL-2RA genes. J Biol Chem 1995; 270:29 862-9.
14. Lin BB, Cross SL, Halden NF, Roman DG, Toledano MB, et al. Delineation of an enhancerlike positive regulatory element in the interleukin-2 receptor alpha-chain gene. Mol Cell Biol 1990; 10:850-3.
15. Shibuya H, Yoneyama M, Nakamura Y, Harada H, Hatakeyama M, et al. The human interleukin-2 receptor beta-chain gene: genomic organization, promoter analysis and chromosomal assignment. Nucleic Acids Res 1990; 18:3697-703.
16. Noguchi M, Adelstein S, Cao X, Leonard WJ. Characterization of the human interleukin-2 receptor gamma chain gene. J Biol Chem 1993; 268:13601-8.
17. Leonard WJ, Noguchi M, Russell SM, McBride OW. The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. Immunol Rev 1994; 138:61-86.
18. Bamford RN, Grant AJ, Burton JD, Peters C, Kurys G, et al. The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 1994; 91:4940-4.
19. Bach EA, Aguet M, Schreiber RD. The IFN-gamma receptor: a paradigm for cytokine receptor signalling. Ann Rev Immunol 1997; 15:563-93.
20. Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signalling by the IL-2 family cytokines. Oncogene 2000; 19:2566-76.
21. Hatakeyama M, Kono T, Kobayashi N, Kawahara A, Levin SD, et al. Interaction of the IL-2 receptor with the src-family kinase p56lck. Science 1991; 252:1523-8.
22. Kobayashi N, Kono T, Hatakeyama M. Functional coupling of the src-family protein tyrosine kinases p59fyn and p53/56lyn with the interleukin 2 receptor. Proc Natl Acad Sci USA 1993; 90:4201-5.
23. Merida I, Diez E, Gaulton GN. IL-2 binding activates a tyrosine-phosphorylated phosphatidylinositol-3-kinase. J Immunol 1991; 147:2202-7.
24. Kuo CJ, Chung J, Florentino DF, Flanagan WM, Blenis J, et al. Rapamycin selectively inhibits interleukin activation of p70 S6 kinase. Nature 1992; 358:70-3.
25. Graves JD, Downward J, Izquierdo-Pastor M, Rayter S, Warne PH, et al. The growth factor IL-2 activates p21 ras proteins in normal human T-lymphocytes. J Immunol 1992; 148:2417-22.
26. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology, 2nd edn. 1994.
27. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self tolerance maintained by activated T-cells expressing IL-2 receptor alpha chains. J Immunol 1995; 155:1151-64.
28. Waldmann TA. The structure, function and expression of interleukin-2 receptors on normal and malignant T-cells. Science 1986; 232:727-32.
29. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998; 70:1-81.
30. Waldmann TA. The interleukin-2 receptor. J Biol Chem 1991; 266:2681-4.
31. Li XC, Roy-Chaudhury P, Hancock WW, et al. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J Immunol 1998; 161:890-6.
32. Soulillou JP. Immunosuppression through inhibition of interleukin-2/interleukin-2 receptor interaction. Transplant Proc 1999; 31(Suppl.):49-51S.
33. Strom TB, Kelley VR, Murphy JR, et al. Interleukin-2 receptor directed therapies. Ann Rev Med 1993; 44:343-53.
34. Lobuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, et al. Mouse/human chimeric monoclonal antibodies in man: kinetics and immune response. Proc Natl Acad Sci USA 1989; 86:4220-4.
35. Williams KA, Thiel M, Zola H. The new generation anti-CD25 monoclonal antbodies. Transplantation 1999; 68:1228-9.
36. Queen C, Schneider WP, Selick HE, Payne PW, et al. A humanised antibody that binds to the interleukin-2 receptor. Proc Natl Acad Sci USA 1989; 86:10029-33.
37. Kozak RW, Atcher RW, Gansow OA, Friedmann AM, Hines JJ, et al. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci 1986; 83:474-8.
38. Kreitman RJ, Bailon P, Chaudhary VK, Fitzgerald DJP, Pastan I. Recombinant immunotoxins containing anti-Tac (Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor expressing human carcinoma. Blood 1994; 83:426.
39. Hwang J, Fitzgerald DT, Adhyas S, Pastan I. Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987; 48:129-36.
40. Foss FM. DAB(389)IL-2 (ONTAK) : a new fusion protein technology. Clin Lymphoma 2000; (Suppl. 1):S27-31.
41. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415-19.
42. Uchiyama T, Hori T, Tsudo M, Wano Y, Umadome H, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest 1985; 76:446-53.
43. Waldmann TA, White JD, Goldmann CK. The IL-2 receptor:a target for monoclonal antibody therapy of HTLV-1 induced adult T-cell leukaemia. Blood 1993; 82:1701-12.
44. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Park CH, et al. Radioimmunotherapy of IL-2 receptor alpha-expressing Adult T-cell leukaemia with Yttrium-90 labelled anti-Tac. Blood 1995; 86:4063-75.
45. Morris JC, Waldmann TA. Advances in Interleukin-2 receptor targeted treatment. Ann Rheum Dis 2000; 59(Suppl.):i109-14.
46. Kreitman RJ, Wilson WH, White JD, Jaffe ES, Giardina S. Phase 1 trial of recombinant immunotoxin anti-Tac Fv-PE38 in patients with haematologic malignancies. J Clin Oncol 2000; 18:1622-36.
47. Kreitman RJ, Wilson WH, Robbins D, Marguiles I, Stetler-Stevenson M, et al. Responses in refractory hairy cell leukaemia to a recombinant immunotoxin. Blood 1999; 94:3340-8.
48. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376-88.
49. Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, et al. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox. Clin Lymphoma 2002; 4:222-8.
50. Nussenblatt RB, Fortin E, Schiffman R, Rizzon L, Smith J, et al. Treatment of non-infectious intermediate and posterior uveitis with the humanized anti-Tac monoclonal antibody: a phase I/II clinical trial. Proc Natl Acad Sci USA 1999; 96:7462-6.
51. Guex-Crosier Y, Raber J, Chan CC, Knete MS, Benichou J. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 1997; 158:452-8.
52. Anasetti C, Hansen JA, Waldmann TA. Treatment of acute Graft-versus-host disease with humanized anti-Tac. Blood 1994; 84:1320-7.
53. Przepiorka D, Kernan NA, Ippoliti C, Pappadopoulous EB, Giralt S, et al. Daclizumab, a humanized anti-IL-2 receptor alpha chain antibody for treatment of acute graft-versus-host disease. Blood 2000; 95:83-9.
54. Kreuger JG, Walters IB, Myazawa M, Gilleaudeau P, Hakimi J, et al. Successful in vivo blockade of CD25 on T-cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43:448-58.
55. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an IL-2 receptor monoclonal antibody. Clin Exp Dermatol 2000; 25:195-7.
56. Mrowietz U, Zhu K, Christophen E. Treatment of severe psoriasis with anti-CD25 monoclonal antibody. Arch Dermatol 2000; 136:675-6.
57. Kagi MK, Heyer G. Efficacy of Basiliximab, a chimeric anti-IL-2 receptor monoclonal antibody in a patient with severe chronic atopic dermatitis. Br J Dermatol 2001; 145:350-1.
58. Brok HP, Tekoppele JM, Hakimi J, Kerwin JA, Nijenhuis EM. Prophylactic and therapeutic effects of Daclizumab on collagen induced arthritis in rhesus monkeys. Clin Exp Immunol 2001; 124:134-41.
59. Sewell KL, Parker KC, Woodworth TG, Reuben J, Swartz W, et al. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum 1993; 36:1223-33.
60. Martin A, Gutierrez E, Muglia J, McDonald CJ, Guzzo C, et al. A multicenter dose escalation trial with denileukin diftitox in patients with severe psoriasis. Am Acad Dermatol 2001; 45:871-81.
61. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double blind phase II multicenter trial. J Am Acad Dermatol 1998; 38:938-44.
62. Matas AJ, Gillingham KJ, Payne WD, Najanan JS. The impact of an acute rejection episode on long term renal allograft survival. Transplantation 1994; 57:857-9.
63. Kirkman RL, Barrett LV, Koltun WA, Diamantstein T. Prolongation of murine cardiac allograft survival by the anti-IL-2 receptor monoclonal antibody AMT-13. Transplant Proc 1987; 19:618-19.
64. Cooper MM, Robbins RC, Waldmann TA, Gansor OA, Clark RE. Use of anti-Tac antibody in primate cardiac xenograft transplantation. Surgical Forum 1988; 39:353-5.
65. Reed MH, Shapiro ME, Strom TB, Milford EL, Carpenter CB, et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 1989; 47:55-9.
66. Vincenti F, Lantz M, Bimbaum J, Garovoy M, Mould D. A phase I trial of humanized anti-IL-2 receptor antibody in renal transplantation. Transplantation 1997; 63:33-8.
67. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, et al. IL-2 receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338:161-5.
68. Nashan B, Light S, Hardie LR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by Daclizumab. Transplantation 1999; 67:110-15.
69. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K. randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350:1193-8.
70. Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, et al. results of 3 year phase III clinical trials with Daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001; 72:839-45.
71. Bumgardner GL, Ramos E, Lin A, Vincenti F. Daclizumab prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function. Transplantation 2001; 72:642-7.
72. Nair MP, Nampoory MR, Johny KV, Costandi JN, Abdulhalim M, et al. Induction immunosuppression with interleukin-2 receptor antibodies in renal transplant recipients. Transplant Proc 2001; 33:2767-9.
73. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, et al. Prevention of rejection in cardiac transplantation by blockade of the IL-2 receptor with a monoclonal antibody. NEJM 2000; 342:613-19.
74. Abu-Elmagd K, Fung J, McGhee W, Martin D, Mazariegos G, et al. The efficacy of Daclizumab for intestinal transplantation: preliminary report. Transplant Proc 2000; 32:1195-6.
75. Carreno MR, Kato D, Weppler JM, Mathew JM, Fuller L, et al. Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants. Transplant Proc 2001; 33:1015-17.
76. Neuhaus P, Kittur D, Salizzoni M, Nashan B, Clarien PA, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomised placebo-controlled trial. Liver Transplant 2002; 8:132-42.
77. Hesse UJ, Troisi R, Jacobs B, Van Vlem B, de Hemptinne B, et al. A single centers clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Clin Transplant 2000; 14:340-4.
78. Sollinger H, Kaplan B, Pescovitz, Philosophe B, Roza A, et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72:1915-19.
79. Nashan B. The IL2 pathway in clinical immunosuppression. Transplant Proc 2001; 33:3072-4.
80. Keown PA, Balshaw, Krueger H, Baladi JF. Economic analysis of basiliximab in renal transplantation. Transplantation 2001; 71:1573-9.
81. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 1995; 13:513-43.
82. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha chains: breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
83. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000; 343:1313-24.
84. Leonard WJ. XSCID: from molecular cause to gene therapy within seven years. Mol Med Today 2000; 6:403-7.
85. Leonard WJ. The molecular basis of XSCID: defective cytokine receptor signalling. Annu Rev Med 1996; 47:229-39.
86. Macchi P, Villa A, Gillani S, Sacco MG, Frattini A, et al. Mutations of Jak3 gene in patients with severe autosomal severe combined immune deficiency. Nature 1995; 377:65-8.